Prior treatment use did not affect the efficacy or safety of topical ruxolitinib cream 1.5% for up to 52 weeks among patients with atopic dermatitis.
Among patients with polycythemia vera, the treatment pairing of Jakafi and Pegasys shows benefits with acceptable toxicity, ...
Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...
The following is a summary of “Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open label, randomized, ...
On Tuesday, Incyte Corporation (NASDAQ:INCY) reported third-quarter revenue of $1.14 billion, up 24% year over year and ...
Ruxolitinib falls under the drug class known as Janus kinase inhibitors (JAK Inhibitors). It is an inhibitor of the JAK1 and ...
AMSTERDAM — Treatment with ruxolitinib cream, 1.5%, achieved rapid and marked reductions in the clinical signs and symptoms of cutaneous lichen planus, including itch and skin pain, both when ...
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that, following feedback from the U.S. Food and Drug ...
0:09 | The 4 approved drugs have different [adverse] effects. Ruxolitinib [Jakafi] is most known for the cytopenias that it causes, and same with fedratinib [Inrebic]. For both of them, anemia, ...
Ruxolitinib cream initiation significantly reduces the use of other topical and systemic therapies, including corticosteroids and biologics, in atopic dermatitis patients. The findings suggest ...
In the new program content, each patient shares defining moments throughout their journeys including how they finally found relief with Opzelura ® (ruxolitinib) cream 1.5%. Opzelura is a ...
"Ruxolitinib cream may be a novel approach to address an unmet medical need in the treatment of milder HS for which there are no currently approved treatments," reported Martina L. Porter ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback